上海市浦东HIV-1感染者抗病毒治疗效果及耐药研究

发布时间：2018-02-16 08:22

本文关键词： HIV- 抗逆转录病毒治疗耐药突变耐药监测 CD计数病毒载量　出处：《现代预防医学》2017年10期 　论文类型：期刊论文

【摘要】：目的了解浦东2014年-2015年进入高效抗逆转录病毒治疗HIV-1感染者随访6~12个月抗病毒治疗效果及继发耐药率。方法建立抗病毒治疗监测队列,检测治疗前及治疗12个月血样中病毒载量并进行CD4计数,评估治疗效果,提取核酸,以巢式RT-PCR方法扩增HIV-1感染者样品HIV-1聚合酶片段,测序,将获得的核酸序列提交至斯坦福大学HIV耐药数据库进行耐药位点分析,观察队列继发耐药率。结果经过12个月抗病毒治疗,84.69%的(83/98)病例CD4 T淋巴细胞上升0~300 cell/μl及以上,病毒载量大于5 000 IU/ml的比例由64.29%(63/98)下降到5.10%(5/98),病毒载量小于50 IU/ml的比例由6.12%(6/98)上升到83.67%(82/98),继发耐药率为2.04%(2/98)。结论治疗队列内病人服药依从性较高,有着良好的抗病毒治疗效果,上海市浦东继发耐药率维持在较低水平,一线治疗药物有效。
[Abstract]:Objective to investigate the efficacy of antiviral therapy and the rate of secondary drug resistance in patients with HIV-1 from 2014 to 2015. Methods to establish a surveillance cohort for antiviral therapy. The viral load and CD4 count were measured before and after 12 months of treatment. The nucleic acid was extracted and the nucleic acid was extracted. The HIV-1 polymerase fragments were amplified by nested RT-PCR and sequenced. The nucleic acid sequence was submitted to Stanford University HIV drug resistance database for drug resistance analysis, and the secondary drug resistance rate was observed. Results after 12 months of antiviral therapy, 84.69% of CD4 T lymphocytes increased 0 ~ 300cell / 渭 l or more. The proportion of viral load greater than 5 000 IU/ml decreased from 64.29% to 5.10%, and the proportion of viral load less than 50 IU/ml increased from 6.1220% 98 to 83.67% 82 / 98, and the secondary drug resistance rate was 2.04% / 98.Conclusion patients in the treatment cohort have high drug compliance and good antiviral therapeutic effect. Shanghai Pudong secondary drug resistance rate maintained at a low level, the first-line treatment is effective.
【作者单位】：上海市浦东新区疾病预防控制中心复旦大学浦东预防医学研究院;
【基金】：浦东新区科委项目:浦东新区艾滋病治疗及新发现感染者基因特性分析及耐药性研究(PKJ2013-Y37)
【分类号】：R512.91

【相似文献】